REVIEW article
Front. Public Health
Sec. Infectious Diseases: Epidemiology and Prevention
Volume 13 - 2025 | doi: 10.3389/fpubh.2025.1680292
Mortality Risk of Carbapenem-Resistant Hypervirulent Klebsiella pneumoniae (CR-hvKP) vs. Classical CR-KP: A Systematic Review and Meta-Analysis
Provisionally accepted- 1Department of Pharmacy, Aerospace Center Hospital, Beijing, China
- 2Beijing Chest Hospital Affiliated to Capital Medical University, Beijing, China
- 3Hohhot Center for Disease Control and Prevention, Inner Mongolia, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Carbapenem-resistant Klebsiella pneumoniae (K. pneumoniae, CR-KP) and hypervirulent K. pneumoniae (hvKP) represent two major clinical threats, due to high antimicrobial resistance and enhanced pathogenicity, respectively. The emergence of carbapenem-resistant hypervirulent K. pneumoniae (CR-hvKP) strains, which combine both traits, has raised concerns about increased mortality risk and public health impact. However, existing evidence on clinical outcomes remains fragmented and inconclusive. To systematically compare the mortality risk between CR-hvKP and classical CR-KP (CR-cKP) infections and to explore the impact of hypervirulence definitions, mortality endpoints, infection types, and clinical settings through subgroup analyses. Methods: We conducted a comprehensive literature search in PubMed, Scopus, Web of Science, and EMBASE up to July 1, 2025. Studies reporting mortality outcomes in patients infected with CR-hvKP and CR-cKP were included. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using a random-effects model. Subgroup analyses were performed to investigate heterogeneity. Sensitivity analysis and Egger's regression test were used to assess robustness and publication bias. Results: Ten studies with a total of 770 patients (224 with CR-hvKP, 546 with CR-cKP) were included, reporting 315 deaths. The pooled OR for mortality associated with CR-hvKP infection was 2.05 (95% CI: 0.89-4.75), indicating a non-significant trend toward higher mortality. Subgroup analyses indicated significantly increased mortality in studies using phenotypic string tests to define hypervirulence (OR = 4.16), but not in those using genotypic definitions (OR = 1.05). Higher mortality trends were also observed for in-hospital mortality, bloodstream infections, and ICU settings. This is a provisional file, not the final typeset article Conclusions: CR-hvKP may be associated with higher mortality risk compared to CR-cKP. The heterogeneity in hypervirulence definitions significantly influences outcome estimates, highlighting the urgent need for standardized diagnostic criteria. These findings underscore the importance of ongoing molecular surveillance, early identification strategies, and targeted infection control measures to mitigate the public health threat posed by CR-hvKP.
Keywords: Klebsiella pneumoniae, Carbapenem resistance, Hypervirulence, CR-hvKp, dual-threat pathogens, ST11 clone, Infection outcomes, Mortality
Received: 05 Aug 2025; Accepted: 16 Oct 2025.
Copyright: © 2025 Chen, Hou, Shi, Gao and Liang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jialiang Chen, chenchen1595@163.com
Guowei Liang, lgw721@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.